Nuvation Bio Logs $18.5M Q1 IBTROZI Revenues, Secures Japan Rights for Safusidenib
Nuvation Bio reported $18.5 million in first-quarter net product revenues for IBTROZI, with over 600 patients treated since its June 2025 launch and more than half of new patients TKI-naïve. The company secured exclusive Japan rights for safusidenib and held $533.7 million in cash and securities at quarter-end.
1. Q1 Financial Performance
Nuvation Bio reported $18.5 million in net product revenues for IBTROZI during the first quarter of 2026, with approximately 200 new patients starting therapy and more than 600 patients treated since launch. The majority of new starts were TKI-naïve, indicating strong first-line adoption.
2. IBTROZI Clinical and Commercial Progress
Pooled data from TRUST-I and TRUST-II studies showed IBTROZI achieved an 89.8% confirmed overall response rate and 46.1-month median progression-free survival in TKI-naïve ROS1+ NSCLC patients; TKI-pretreated patients saw a 55.8% response rate and 9.7-month PFS. IBTROZI was added to NCCN CNS Cancer Guidelines and its EMA marketing application has entered standard review.
3. Safusidenib Rights Acquisition
Nuvation Bio acquired exclusive Japan development and commercialization rights for safusidenib from Daiichi Sankyo, gaining full ownership of global clinical data and programs. The company plans to advance the pivotal Phase 3 SIGMA study for high-risk IDH1-mutant glioma.
4. Strong Balance Sheet
As of March 31, 2026, Nuvation Bio held $533.7 million in cash, cash equivalents and marketable securities, providing runway to support ongoing clinical trials, pipeline expansion and upcoming commercial launches.